News - Appointments

Addex Therapeutics Ltd has appointed Darryle Schoepp as chair of its newly created scientific advisory board to help direct development of the company’s allosteric modulators for neurological disorders.

Mark Truesdale has been promoted to the position of chief executive of Solentim Ltd from chief marketing officer to help grow the company’s instrumentation business. He was previously a marketing executive at Thermo Fisher Scientific.

Sweden-based Oncopeptides AB has appointed Karolina Vilval as general counsel. Ms Vilval previously worked as associate legal director at Gilead Sciences Sweden AB for the business unit oncology, HIV and inflammation.

Lars Nieba has been appointed interim chief executive of Nordic Nanovector ASA following the departure of the previous CEO Eduardo Bravo.

CureVac AG, the Germany-based developer of messenger RNA (mRNA) therapies, has created a new division for rare diseases and hired Alan Kimura, an experienced pharma executive, to lead it.

Robert Duggan, a member of the board of directors of Summit Therapeutics Plc, has been appointed executive chairman to help guide development of the company’s candidate antibiotics.

Marina Udier has been promoted to chief executive officer at Nouscom AG, having served in this role on an interim basis since May 2019. She is joined on the management team by Patricia Delaite, newly appointed as chief medical officer.

Andrew Jones, a former Barclays Bank executive, has joined the board of Atlantic Healthcare Plc as a non-executive director to help manage the company’s specialist pharma business.

Adaptimmune Therapeutics Plc has appointed Gavin Wood as chief financial officer, effective 1 April, as it prepares to commercialise its first immunotherapy for cancer in 2022.

Fiona Withey has been appointed chief executive officer of UK-based TrakCel Ltd to help lead the growth of the company’s services for the autologous and allogeneic cell and gene therapy sectors.